Hypotension - Pipeline Review, H2 2019
Hypotension - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension - Pipeline Review, H2 2019, provides an overview of the Hypotension (Cardiovascular) pipeline landscape.
Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Treatment is required for patients with signs and symptoms.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypotension - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hypotension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypotension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypotension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Unknown stages are 2, 2, 1, 2 and 1 respectively.
Hypotension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension - Pipeline Review, H2 2019, provides an overview of the Hypotension (Cardiovascular) pipeline landscape.
Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Treatment is required for patients with signs and symptoms.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypotension - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hypotension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypotension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypotension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Unknown stages are 2, 2, 1, 2 and 1 respectively.
Hypotension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypotension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Hypotension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypotension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypotension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypotension (Cardiovascular)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypotension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypotension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hypotension - Overview
Hypotension - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypotension - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypotension - Companies Involved in Therapeutics Development
Cerecor Inc
Handa Pharmaceuticals LLC
La Jolla Pharmaceutical Company
Theravance Biopharma Inc
TrioxBio Inc
Hypotension - Drug Profiles
ampreloxetine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
angiotensin II acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dopamine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HND-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTR-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phenylephrine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rislenemdaz - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypotension - Dormant Projects
Hypotension - Product Development Milestones
Featured News & Press Releases
Jul 22, 2019: Theravance Biopharma reports new data from phase 2 study of ampreloxetine (TD-9855) in oral presentation at 32nd European Neurology Congress
Jun 28, 2019: La Jolla Pharmaceutical Company receives positive CHMP opinion for GIAPREZA (angiotensin II) for the treatment of refractory Hypotension in adults with septic or other distributive shock
Jun 18, 2019: Theravance Biopharma reports new data from phase 2 study of Ampreloxetine (TD-9855) in presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress
Jun 11, 2019: BrePco Biopharma announce the presentation of selected results of late-stage clinical trial in extremely premature neonates
Mar 25, 2019: Theravance Biopharma announces Ampreloxetine (TD-9855) phase 2 study results selected for oral presentation at 32nd European Neurology Congress
Jan 29, 2019: Theravance doses first patient in Phase III trial of ampreloxetine
Aug 01, 2018: Theravance Biopharma reports positive top-line four-week data from phase 2 trial of TD-9855 for the treatment of symptomatic neurogenic orthostatic hypotension
May 29, 2018: TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten for the Treatment of Intradialytic Hypotension
Sep 25, 2017: La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018
Sep 20, 2017: Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State
Aug 28, 2017: La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501
Aug 08, 2017: La Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501
May 21, 2017: Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine
Feb 27, 2017: La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501
Nov 30, 2015: La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Hypotension - Overview
Hypotension - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypotension - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypotension - Companies Involved in Therapeutics Development
Cerecor Inc
Handa Pharmaceuticals LLC
La Jolla Pharmaceutical Company
Theravance Biopharma Inc
TrioxBio Inc
Hypotension - Drug Profiles
ampreloxetine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
angiotensin II acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dopamine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HND-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTR-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phenylephrine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rislenemdaz - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypotension - Dormant Projects
Hypotension - Product Development Milestones
Featured News & Press Releases
Jul 22, 2019: Theravance Biopharma reports new data from phase 2 study of ampreloxetine (TD-9855) in oral presentation at 32nd European Neurology Congress
Jun 28, 2019: La Jolla Pharmaceutical Company receives positive CHMP opinion for GIAPREZA (angiotensin II) for the treatment of refractory Hypotension in adults with septic or other distributive shock
Jun 18, 2019: Theravance Biopharma reports new data from phase 2 study of Ampreloxetine (TD-9855) in presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress
Jun 11, 2019: BrePco Biopharma announce the presentation of selected results of late-stage clinical trial in extremely premature neonates
Mar 25, 2019: Theravance Biopharma announces Ampreloxetine (TD-9855) phase 2 study results selected for oral presentation at 32nd European Neurology Congress
Jan 29, 2019: Theravance doses first patient in Phase III trial of ampreloxetine
Aug 01, 2018: Theravance Biopharma reports positive top-line four-week data from phase 2 trial of TD-9855 for the treatment of symptomatic neurogenic orthostatic hypotension
May 29, 2018: TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten for the Treatment of Intradialytic Hypotension
Sep 25, 2017: La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018
Sep 20, 2017: Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State
Aug 28, 2017: La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501
Aug 08, 2017: La Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501
May 21, 2017: Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine
Feb 27, 2017: La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501
Nov 30, 2015: La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Hypotension, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Hypotension - Pipeline by Cerecor Inc, H2 2019
Hypotension - Pipeline by Handa Pharmaceuticals LLC, H2 2019
Hypotension - Pipeline by La Jolla Pharmaceutical Company, H2 2019
Hypotension - Pipeline by Theravance Biopharma Inc, H2 2019
Hypotension - Pipeline by TrioxBio Inc, H2 2019
Hypotension - Dormant Projects, H2 2019
Number of Products under Development for Hypotension, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Hypotension - Pipeline by Cerecor Inc, H2 2019
Hypotension - Pipeline by Handa Pharmaceuticals LLC, H2 2019
Hypotension - Pipeline by La Jolla Pharmaceutical Company, H2 2019
Hypotension - Pipeline by Theravance Biopharma Inc, H2 2019
Hypotension - Pipeline by TrioxBio Inc, H2 2019
Hypotension - Dormant Projects, H2 2019
LIST OF FIGURES
Number of Products under Development for Hypotension, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Cerecor Inc
Handa Pharmaceuticals LLC
La Jolla Pharmaceutical Company
Theravance Biopharma Inc
TrioxBio Inc
Number of Products under Development for Hypotension, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Cerecor Inc
Handa Pharmaceuticals LLC
La Jolla Pharmaceutical Company
Theravance Biopharma Inc
TrioxBio Inc
